A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (NCT06072781)
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
🩺 Plain-English Summary (8th-Grade Level)
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Who can join: Review the eligibility criteria below.
Location: HonorHealth — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (106 Sites)
Showing the first 25 of 106 sites.
- HonorHealth — Phoenix, Arizona
- University of Arkansas — Little Rock, Arkansas
- UCLA Health — Los Angeles, California
- UC Davis — Sacramento, California
- University of California, San Francisco — San Francisco, California
- Yale University — New Haven, Connecticut
- Florida Cancer Specialists - South — Fort Myers, Florida
- Mount Sinai — Miami Beach, Florida
- AdventHealth — Orlando, Florida
- Moffitt Cancer Center — Tampa, Florida
- Florida Cancer Specialists Research East — West Palm Beach, Florida
- Winship Cancer Institute at Emory University — Atlanta, Georgia
- NorthShore University HealthSystem — Evanston, Illinois
- Louisiana State University — New Orleans, Louisiana
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- Karmanos Cancer Center — Detroit, Michigan
- Minnesota Oncology Hematology — Minneapolis, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Atrium Health — Charlotte, North Carolina
- Cleveland Clinic Foundation — Cleveland, Ohio
- Ohio State — Hilliard, Ohio
- University of Oklahoma Medical Center — Oklahoma City, Oklahoma
- Willamette Valley Cancer Institute — Eugene, Oregon
📞 Contact the Study Coordinator
Phone: (781) 292-4204
Email: RAMP301TrialSupport@verastem.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Low Grade Serous Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.